OXGENE
We provide pioneering companies with advanced technology and service solutions to accelerate the transition between laboratory research and clinical manufacture. OXGENE is the innovation arm of WuXi Advanced Therapies, providing expert design and engineering services for viral vector optimisation and cell line development, seamlessly integrated with WuXi Advanced Therapies’ GMP manufacturing and testing platforms. We provide pioneers with advanced technology and service solutions to accelerate the transition between laboratory research and clinical manufacture. Invention and innovation to advance and improve the development and delivery of cell and gene therapies. Ultimately, our complete end-to-end solutions support pioneering companies to deliver breakthrough cell and gene therapies to the patients who need them in the fastest possible time. By combining WuXi ATU's world class cell and gene therapy CTDMO platform with OXGENE's innovative capabilities, we will be able to provide transformative solutions for our customers. WuXi Advanced Therapies is a global Contract Testing, Development and Manufacturing Organization (CTDMO) dedicated to accelerating progress and time to market for cell and gene therapies. The challenge of scalable AAV manufacture for gene therapies, and how to overcome it.
This company is:
Verified
OXGENE - Cell line development - OXGENE
OXGENE’s team of cell line engineering experts design a strategy and use our optimised workflow and high throughput screening platform to maximise project success across multiple applications,...
Verified
Transient LV Production Systems - OXGENE
Cookie Preferences | CELL THERAPY SOLUTIONS | TRANSIENT LV PRODUCTION SYSTEMS | "Switching to OXGENE's Lenti viral vector plasmids gave an instant 10-fold improvement in lentiviral yield" | Dr Yiyu Dong, Associate Director, Process Development. WuXi Advanced Therapies | Transient Lentiviral Production Systems | High transfection efficiency in cells at both early and late passages in multiple HEK293 cell lines. | Lenti viral vector plasmids give consistently high yields in suspension cells | Lentiviral & Plasmid Libraries | Access our Transient Lentiviral Solutions | You might be interested in | High-Throughput Lentiviral Library Construction | Lentiviral Transient and Stable Platforms | OXGENE Case Study - TiCARos | Accelerating the Clinical Success of Gene Therapies through Viral Vector Engineering | Lentiviral packaging and producer cell lines | View / Download Resource
Verified
TESSA: Scalable AAV Production - OXGENE
Cookie Preferences | GENE THERAPY SOLUTIONS | TESSA: SCALABLE AAV PRODUCTION | "Overall, TESSA™ enables us to test new constructs much faster and cheaper now which is why we like to keep using it." | Dr Harald Hartweger, The Rockefeller University | Tetracycline enabled self silencing adenovirus (TESSA™) technology | Evaluate TESSA™ technology | How it works | Advantages | Adenoviral structural genes are regulated by negative feedback loop | Using two TESSA™ vectors improves rAAV yield and infectivity | Adding TESSA™ to rAAV seed stock continues rAAV propagation | Source of rAAV seed stock does not affect final yield | You might be interested in | Redefining AAV Manufacturing: The Time Is Now | Optimizing Adeno-Associated Virus (AAV) Manufacturing | Advances in AAV analytics | A necessary transition: why viral vector production for gene therapy needs to evolve | Cell & Gene Therapy Insights - OXGENE Fast Facts | GEN Webinar - Scalable Plasmid Free AAV Manufacturing | GEN Webinar - Uncovering the Secrets of AAV for Improved CGT | BPI Webinar - OXGENE's TESSA™ Technology | Are you ready for GMP Manufacture? | View / Download Resource
View all products
Keywords
Industries
OXGENE Case Study - TiCARos - OXGENE
TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of next generation immunotherapies...
Where is Oxford Genetics located?
The company Oxford Genetics is located in Cherwell District, England, United Kingdom. It's worth noting that the company may has more corporate locations
How many employees does Oxford Genetics approximately have?
As of the latest available information Oxford Genetics has around 51-100 employees worldwide.
When was Oxford Genetics founded?
Oxford Genetics was founded in 2011
In which industries does Oxford Genetics mainly work?
The company Oxford Genetics has it's main focus in the industries of Science and Engineering, Biotechnology, Health Care
What is the current company status of Oxford Genetics?
Based on the founding year and the amount of employees the company Oxford Genetics seems to be a Medium-Sized Company at the current state. Note that over time that status can change
Genezen Laboratories
United States
1-10 Employees
2014
WuXi AppTec
China
10001+ Employees
2000
Be The Match BioTherapies
United States
1001-5000 Employees
2016
OcyonBio
United States
11-50 Employees
WuXi Discovery Services
China
10001+ Employees
2000
ExcellGene
Switzerland
11-50 Employees
2001
ZEDGENE
France
1-10 Employees
2018
Affinia Therapeutics
United States
51-100 Employees
2019
Topics which have been searched by others and may be interesting for you:
